Prescription drug spending in the US drives healthcare spending primarily due to high US drug pricing, not necessarily because of the number of drugs that providers prescribe use, a Commonwealth Fund...
The National Association of Medicaid Directors (NAMD) is recommending that CMS approve Medicare coverage for Alzheimer’s disease therapies.
“The outcome of Medicare’s coverage...
CMS has started a national coverage determination analysis and will establish Medicare coverage policies for the new Alzheimer’s drug, aducanumab.
Aducanumab is a monoclonal antibody that...
